Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04856137 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I/II Study of Diffuse Large B-cell Lymphoma

Study acronym: DLBL
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 23, 2021 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
For continuous variables, mean, median, minimum, and maximum will be used for the descriptive purpose. For categorical variables, frequency and percentage will be used for descriptive statistics. The variables of OS will be estimated by the Kaplan-Meier method. Differences between groups will be calculated using the log-rank test for univariate analysis. Cox's proportional hazards model will be employed to test independent prognostic factors. All calculations will be performed using the Statistical Package of Social Sciences software, version 17.0 (SPSS, Inc., Chicago, IL, USA). The level of statistical significance will be set at 0.05 for all tests.
Trial Details
NCT Number NCT04856137
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, Shin Kong Wu Huo-Shih Memorial Hospital
Conditions
(from sponsor)		 Refractory Diffuse Large B-cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov